Senores Pharmaceuticals Ltd

AGM Details

• AGM held Sept 25, 2026 at 11:31 IST via VC/OAVM.
• Voting cut-off date: Sept 18, 2026.
• Remote e-voting period: Sept 22–24, 2026.
• VC attendance: Promoter Group 9, Public 40.

Key Resolutions

• Resolution 1: Ordinary; adopt Audited standalone and Consolidated Financial Statements for year ended Mar 31, 2026.
• Resolution 2: Ordinary; re-appoint Majmudar, retires by rotation.
• Resolution 3: Ordinary; re-appoint Arpit Shah, retires by rotation.
• Resolution 4: Special; Viranchi Shah as non-exec independent director for 5 years.
• Resolution 5: Special; approve Senores Employees Stock Option Scheme 2026.
• Resolution 6: Special; approve ESOP grants to subsidiary employees under Scheme 2026.

Voting Results

• Resolution 1: Passed; 100% in favour on votes polled.
• Resolution 2: Passed; Majmudar's 3,000 votes excluded from passing.
• Resolution 3: Passed; 93.78% in favour, 6.22% against.
• Resolution 4: Passed; 100% in favour.
• Resolution 5: Passed; 93.81% in favour, 6.19% against.
• Resolution 6: Passed; 93.81% in favour, 6.19% against.

Dividend

• Dividend: No dividend declared or proposed.

Director Changes

• Majmudar re-appointed as director (retiring by rotation).
• Arpit Deepakkumar Shah re-appointed as director (retiring by rotation).
• Viranchi Arvindbhai Shah appointed as non-executive independent director for five-year term.

Other Material Approvals

• Approval of Senores Pharmaceuticals Employee Stock Option Scheme 2026.
• Approval to grant ESOP to subsidiary employees under Scheme 2026.

AGM Details

• Date and time: 25 Sep 2026, 11:31 AM–12:02 PM IST.
• Mode: VC/OAVM; attended by 49 members.
• Remote e-voting window: Sep 22–24, 2026; voting continued 15 minutes after AGM.

Key Resolutions

• Adopt audited standalone and consolidated financial statements for FY ended March 31, 2026 (Ordinary).
• Re-appoint Sanjay Majmudar by rotation (Ordinary).
• Re-appoint Arpit Shah by rotation (Ordinary).
• Appoint Viranchi Shah as Non-Executive Independent Director for five years (Special).
• Approve ESOP Scheme 2026 (Special).
• Grant ESOPs to subsidiary employees under the scheme (Special).

Voting Results

• Voting results are not disclosed in the filing.

Director Changes

• Majmudar re-appointed by rotation (Director).
• Arpit Shah re-appointed by rotation (Director).
• Viranchi Shah appointed as Non-Executive Independent Director for five-year term.

ESOP Approvals

• Approval of Senores Pharmaceuticals Employee Stock Option Scheme 2026.
• Grant of ESOPs to subsidiary employees under the scheme approved.

Board meeting date

• Board meeting date to approve unaudited results will be intimated separately.

Clarification on volume movement and SEBI LODR compliance

• No undisclosed/price-sensitive information exists; company will continue to inform exchanges of all material events.

USFDA inspection outcome

• USFDA completed inspection of Apnar Pharma's Vadodara facility from Sept 7–11, 2026.
• No GMP observations; one minor procedural observation; response to be submitted within timeframe.

Financial performance

• Consolidated revenue rose to ₹679.69 Cr in FY26, up 62.8% YoY.
• PAT climbed to ₹115.38 Cr, up 97% YoY.
• EBITDA margin stood at 34.05% for FY26.
• Consolidated EPS: ₹26.39 per share.
• Dividends declared: none for FY2025-26.
• IPO warrants: 11.70 lakh issued; ₹23.75 Cr raised.
• Net Debt: ₹281.54 Cr; gearing 0.29x.

Growth & strategy

• US Regulated Markets contribute ~70% of Regulated revenue.
• ANDA portfolio expanded to 51 products; 21 launched; 27 under development.
• 51% Zoraya acquisition strengthens US market access; 75% Apnar Pharma stake acquired; 25% to close FY27.
• Amerisyn JV (70%) strengthens front-end US government channel.
• Atlanta and Chhatral capacity expansions target sterile injectables and onshore APIs.

Portfolio & pipeline

• ANDA portfolio growth complements CDMO/CMO strategy.
• R&D pipeline includes 27 molecules across stages; 6 filed for approvals.
• Emerging Markets: 40+ countries with 478 registered products; EU registration achieved.

Capital allocation & IPO proceeds

• IPO proceeds: ₹105.02 Cr unutilized as of 31 Mar 2026; monitored by CARE Ratings.
• 0%+ objects reallocated to inorganic growth and general corporate purposes.
• 11,70,000 convertible warrants issued to promoter group; ₹23.75 Cr received.

Manufacturing & operations

• US FDA Atlanta facility expanded; onshore controlled-substances manufacturing; four lines targeted for sterile injectables.
• Naroda API plants strengthened; Chhatral WHO-GMP facility supports Emerging Markets.
• CDMO/CMO platform supports global product lifecycle, regulatory filings, and manufacturing scalability.

Governance & leadership

• Viranchi Arvindbhai Shah appointed as Non-Executive Independent Director for five years from Aug 26, 2026.
• Board comprises 12 directors; new leadership hires across R&D, strategy, and quality.
• Shilpa Sharma appointed Company Secretary & Compliance Officer from Aug 26, 2026.

ESG, CSR & risk management

• First-year Business Responsibility & Sustainability Report (BRSR) published.
• CSR spend: ₹0.06 Cr; 2% of average net profit allocated for CSR obligations.
• Ongoing risk management framework addresses market, regulatory, and supply-chain risks.

Outlook & risks

• Growth anticipated across Regulated Markets, Emerging Markets, Branded Generics, and API platform.
• Downside risks include global trade fragmentation and currency volatility.
• India remains a growth engine with supportive government initiatives and API industry expansion.

Dividend policy

• Board retained profits for growth; no dividend declared for FY2025-26.

Meeting Details

• Date and time: 02 September 2026, 11:00 AM IST onwards.
• Type: Group / 1x1 meetings; Mode: Physical at Mumbai.
• Hosted by: Elara Capital.

Participants

• Key participants: company officials; senior management to attend.

Purpose

• Purpose: analyst/institutional investor meeting based on public information.